Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 1Cardiotoxicity 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 8fludarabine phosphate 7fludarabine 5Busulfan 5Mycophenolic Acid 4Melphalan 4Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Filgrastim 3Azacitidine 3venetoclax 2thymoglobulin 2Tacrolimus 2Rituximab 2Injections 2Hematopoietic Stem Cell Transplantation 2Granulocyte Colony-Stimulating Factor 2Cytarabine 2Cyclosporins 2Clofarabine 2Bone Marrow Transplantation 2Antilymphocyte Serum 2sulforaphane 1ruxolitinib 1pegylated granulocyte colony-stimulating factor 1monalizumab 1ivosidenib 1enasidenib 1cedazuridine 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Anemia, Refractory, with Excess of Blasts × sulforaphane × Clear all
NCT07297576 2025-12-30

Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation

Institute of Hematology & Blood Diseases Hospital, China

Phase NA Recruiting
36 enrolled
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡